Viewing Study NCT01138332


Ignite Creation Date: 2025-12-24 @ 9:40 PM
Ignite Modification Date: 2025-12-28 @ 6:49 AM
Study NCT ID: NCT01138332
Status: COMPLETED
Last Update Posted: 2015-05-06
First Post: 2010-06-04
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Biomarkers in Young Patients With Acute Myeloid Leukemia
Sponsor: Children's Oncology Group
Organization:

Study Overview

Official Title: Stat3 Signaling Pathway Aberrancies in Pediatric AML
Status: COMPLETED
Status Verified Date: 2015-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in tissue samples from young patients with acute myeloid leukemia.
Detailed Description: OBJECTIVES:

* Determine the frequency of ligand-independent phosphorylation of Stat3 in a small cohort of samples from pediatric patients with acute myeloid leukemia including, but not limited to, samples known to express mutated c-kit.
* Measure the level of Stat3 phosphorylation in these samples after stimulation of three key cytokine receptors expressed on hematopoietic cells IL-6R, G-CSFR, and c-kit.

OUTLINE: Cryopreserved samples are analyzed for levels of various components of the Stat3 pathway via western blotting.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
COG-AAML10B10 OTHER Children's Oncology Group View
CDR0000671489 OTHER Clinical Trials.gov View
NCI-2011-02226 REGISTRY CTRP (Clinical Trial Reporting Program) View